ImmunityBio Price Target Raised to $15 as Anktiva Sales Soar 700%
H.C. Wainwright sets a $15 price target, implying 54.56% upside for ImmunityBio. Flagship Anktiva achieved a 700% sales increase in 2025 and 20% quarter-over-quarter growth, while the stock has quintuplied this year on a market cap of approximately $9.57 billion.
1. Price Target and Stock Reaction
On February 23, 2026, H.C. Wainwright assigned ImmunityBio a $15 price target, reflecting a 54.56% potential upside from its $9.71 share price. This outlook coincided with a 16% post-earnings surge and an 11.67% rally on the same day.
2. Anktiva’s Sales Momentum
Anktiva, ImmunityBio’s lead immunotherapy, delivered a 700% sales increase in 2025 and 20% quarter-over-quarter growth in Q4. The biologic’s application in bladder cancer unresponsive to Bacille Calmette-Guérin treatment drives the majority of U.S. revenue.
3. Market Capitalization and Trading Dynamics
ImmunityBio’s market capitalization stands near $9.57 billion, supported by daily trading volume of 73.67 million shares. Share prices fluctuated between $9.59 and $11, nearing a 52-week high after quintupling year-to-date.
4. Progress on Profitability and Platform
The Cancer BioShield platform stimulates natural killer, cytotoxic T and memory T cells to broaden immunotherapy efficacy. Despite a $0.06 loss per share in Q4, earnings have improved for three consecutive quarters, signaling advancing profitability.